{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05123365",
            "orgStudyIdInfo": {
                "id": "20216930"
            },
            "secondaryIdInfos": [
                {
                    "id": "UCI 20-50",
                    "type": "OTHER",
                    "domain": "CFCCC"
                }
            ],
            "organization": {
                "fullName": "University of California, Irvine",
                "class": "OTHER"
            },
            "briefTitle": "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",
            "officialTitle": "An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "an-optimal-dose-finding-study-of-n-acetylcysteine-in-patients-with-myeloproliferative-neoplasms"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-05",
            "studyFirstSubmitQcDate": "2021-11-05",
            "studyFirstPostDateStruct": {
                "date": "2021-11-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-16",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Angela G. Fleischman",
                "investigatorTitle": "Associate Professor",
                "investigatorAffiliation": "University of California, Irvine"
            },
            "leadSponsor": {
                "name": "University of California, Irvine",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).",
            "detailedDescription": "This is a phase I/II open-label clinical trial determining the optimal biological dose (OBD) of N-acetylcysteine in subjects with myeloproliferative neoplasms. These are subjects who have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF)."
        },
        "conditionsModule": {
            "conditions": [
                "Myeloproliferative Neoplasm",
                "MPN",
                "Essential Thrombocythemia",
                "Polycythemia Vera",
                "Myelofibrosis"
            ],
            "keywords": [
                "MPN",
                "Myeloproliferative Neoplasm",
                "Essential Thrombocytemia",
                "Polycythemia Vera",
                "Myelofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 27,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Level 1 (DL1)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients take N-Acetylcysteince 600 mg orally twice daily.\n\nThis is the starting dose level for the study.",
                    "interventionNames": [
                        "Drug: N-Acetylcysteine"
                    ]
                },
                {
                    "label": "Dose Level 2 (DL2)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients take N-Acetylcysteince 1200 mg orally twice daily.\n\nIf DL1 is well tolerated, the next cohort will progress to this dose level.",
                    "interventionNames": [
                        "Drug: N-Acetylcysteine"
                    ]
                },
                {
                    "label": "Dose Level 3 (DL3)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients take N-Acetylcysteince 1800 mg orally twice daily.\n\nIf DL2 is well tolerated, the next cohort will progress to this dose level.",
                    "interventionNames": [
                        "Drug: N-Acetylcysteine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "N-Acetylcysteine",
                    "description": "Given PO",
                    "armGroupLabels": [
                        "Dose Level 1 (DL1)",
                        "Dose Level 2 (DL2)",
                        "Dose Level 3 (DL3)"
                    ],
                    "otherNames": [
                        "N-AC"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Optimal Biological Dose (OBD) of N-Acetylcysteine",
                    "description": "Determination of the optimal biological dose (OBD) will be utilized to evaluate the safety and tolerability of N-AC as a treatment for patients with MPN. Optimal biological dose is defined as the therapeutic dose that possesses the highest efficacy probability while inducing acceptable toxicity",
                    "timeFrame": "From the start date of treatment until 7 days after completion of treatment or removal of treatment due to disease progression, toxicity, delay of treatment, or withdrawal of treatment, whichever came first, up to 8 weeks."
                },
                {
                    "measure": "Proportion of subjects who achieve 30% reduction of MPN-SAF Total symptom score (MPN-TSS)",
                    "description": "MPN-SAF Total symptom score (MPN-TSS) is a validated tool to objectively measure the burden of symptoms associated with MPN. Baseline TSS will be defined as the average of the daily TSS of 7 consecutive days immediately prior to beginning N-AC. The end of study MPN-TSS will be defined as the average of the daily TSS of 7 consecutive days during week 8.",
                    "timeFrame": "7 days prior to beginning treatment until end of treatment, average of 9 weeks."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \u226518 years of age\n* Have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis (MF) according to the 2016 WHO criteria\n* Has not taken interferon-alpha or a JAK inhibitor (such as ruxolitinib or fedratinib) for treatment of MPN in the past 28 days before enrollment.\n* May continue on current MPN treatment, including aspirin, hydroxyurea, or anagrelide. Therapeutic phlebotomies should continue per the patient's usual regimen.\n* Has not taken N-Acetylcysteine (N-AC) or preparations containing N-AC in the past 28 days before enrollment.\n* Baseline MPN-TSS score of \u2265 10 at the time of enrollment.\n* Peripheral blast count \\<10% during Screening.\n* Free of other active or metastatic malignancies other than localized skin cancer.\n* Amenable to blood draws and symptom assessments.\n* Agree to the use of contraceptives. Female subjects of childbearing potential and their male partners, or male subjects who have female partners of childbearing potential, should both use an effective contraception method during the study and continue to use contraception for 60 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) questionnaire score of \u22653\n* Currently pregnant or planning on being pregnant within the study period.\n* Currently breastfeeding.\n* Known uncontrolled active viral or bacterial infection.\n* Significant impairment of major organ function defined as\n\n  1. Serum creatinine clearance less than 50 ml/min (calculated with Cockroft-Gault formula).\n  2. Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.\n  3. Platelets \\< 100 \u00d7 10\\^9/L\n  4. Hgb \\< 10 g/dL\n  5. ANC \\< 0.75 \u00d7 10\\^9/L\n* Known history of allergic reaction to N-AC.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Angela Fleischman, MD, PhD",
                    "role": "CONTACT",
                    "phone": "(714) 456-8000",
                    "email": "agf@hs.uci.edu"
                },
                {
                    "name": "University of California Irvine Medical Center",
                    "role": "CONTACT"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Angela Fleischman, MD, PhD",
                    "affiliation": "Chao Family Comprehensive Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Irvine",
                    "state": "California",
                    "zip": "92617",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Angela G Fleischman, MD PhD",
                            "role": "CONTACT",
                            "phone": "949-999-2400",
                            "email": "agf@uci.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.66946,
                        "lon": -117.82311
                    }
                },
                {
                    "facility": "Chao Family Comprehensive Cancer Center, University of California, Irvine",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000011087",
                    "term": "Polycythemia Vera"
                },
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000011086",
                    "term": "Polycythemia"
                },
                {
                    "id": "D000013922",
                    "term": "Thrombocytosis"
                },
                {
                    "id": "D000013920",
                    "term": "Thrombocythemia, Essential"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000019046",
                    "term": "Bone Marrow Neoplasms"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001791",
                    "term": "Blood Platelet Disorders"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13972",
                    "name": "Polycythemia Vera",
                    "asFound": "Polycythemia Vera",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13971",
                    "name": "Polycythemia",
                    "asFound": "Polycythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16681",
                    "name": "Thrombocytosis",
                    "asFound": "Thrombocythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16679",
                    "name": "Thrombocythemia, Essential",
                    "asFound": "Essential Thrombocythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21070",
                    "name": "Bone Marrow Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5072",
                    "name": "Blood Platelet Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4614",
                    "name": "Polycythemia Vera",
                    "asFound": "Polycythemia Vera",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2144",
                    "name": "Essential Thrombocythemia",
                    "asFound": "Essential Thrombocythemia",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000111",
                    "term": "Acetylcysteine"
                },
                {
                    "id": "C000030905",
                    "term": "N-monoacetylcystine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000005100",
                    "term": "Expectorants"
                },
                {
                    "id": "D000019141",
                    "term": "Respiratory System Agents"
                },
                {
                    "id": "D000016166",
                    "term": "Free Radical Scavengers"
                },
                {
                    "id": "D000000975",
                    "term": "Antioxidants"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3475",
                    "name": "Acetylcysteine",
                    "asFound": "Macular",
                    "relevance": "HIGH"
                },
                {
                    "id": "M244107",
                    "name": "N-monoacetylcystine",
                    "asFound": "Band",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8243",
                    "name": "Expectorants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21137",
                    "name": "Respiratory System Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4292",
                    "name": "Antioxidants",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}